Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for AML patients: Heart-Safe drug combo enters trials

NCT ID NCT07486726

First seen Apr 21, 2026 · Last updated May 24, 2026 · Updated 6 times

Summary

This study tests a three-drug combination (aclarubicin, azacitidine, venetoclax) for people with acute myeloid leukemia (AML), including those newly diagnosed or whose cancer has returned. The goal is to find the safest dose and see if the combo improves remission rates. About 112 adults aged 18 and older will take part, focusing on those who cannot tolerate standard intensive chemotherapy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai

    Shanghai, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Shanghai Jing'an District Beizhan Hospital

    Shanghai, China

    Contact Phone: •••-•••-••••

  • Shanghai Traditional Chinese Medicine Hospital

    Shanghai, China

    Contact Email: •••••@•••••

  • Tongren Hospital, Shanghai Jiao Tong University School of Medicine

    Shanghai, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.